Nordic Bioscience
Financials
Estimates*
EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | - | 36.1m | 41.8m |
% growth | - | - | - | - | - | - | 16 % |
EBITDA | - | 10.5m | 16.4m | 13.3m | 16.2m | 18.1m | 20.1m |
% EBITDA margin | - | - | - | - | - | 50 % | 48 % |
Profit | 2.6m | 6.8m | 10.2m | 9.9m | 12.4m | 14.0m | 15.1m |
% profit margin | - | - | - | - | - | 39 % | 36 % |
R&D budget | 7.2m | 8.5m | 11.8m | 12.6m | 15.1m | 10.9m | 11.4m |
R&D % of revenue | - | - | - | - | - | 30 % | 27 % |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Grant | ||
$100m | Growth Equity VC | ||
Total Funding | €90.9m |
Recent News about Nordic Bioscience
EditNordic Bioscience is a specialized company focused on biomarker development and clinical trials, particularly in the fields of rheumatology and fibrosis. Operating in the biotechnology and pharmaceutical sectors, the company leverages over 25 years of experience to offer customized assay development and research programs. Nordic Bioscience serves pharmaceutical companies, research institutions, and healthcare providers by providing high-quality biomarker analysis and clinical trial services. The company generates revenue through service contracts, research collaborations, and licensing agreements. Its business model is built on delivering precision medicine solutions using unique biomarker technologies, which help in the early detection and treatment of diseases. The company is privately owned, allowing for swift decision-making and adaptability to market needs.
Keywords: biomarkers, clinical trials, precision medicine, rheumatology, fibrosis, assay development, pharmaceutical, biotechnology, research programs, healthcare.